Directly referring to the US$75m acquisition of Rubicon...

Directly referring to the US$75m acquisition of Rubicon Genomics, is a bit of misleading.
The US$75m consideration was for the whole company, not just PicoPLEX.

Rubicon Genomics, has three products: ThruPLEX, PicoPLEX and TransPLEX.
They took 8 years to get Rubicon Genomics from the scratch to US$75m, also there were at least two capital raisings (one US$2m + one US$5.5m).

Rubicon Genomics, Inc. develops nucleic acid library preparation and companion products that enable highly sensitive analysis of clinical research samples around the world. It offers ThruPLEX DNA-seq Kit, a high sensitivity ligation-based amplification solution; ThruPLEX Tag-seq Kit, a high sensitivity ligation-based amplification with molecular tags; ThruPLEX Plasma-seq Kit, a high sensitivity ligation-based amplification solution; PicoPLEX DNA-seq Kit, a quasi-random primed linear amplification solution; PicoPLEX WGA Kit, a quasi-random primed linear amplification solution; and TransPLEX CWTA Kit, a quasi-random primed amplification solution. The company sells its products through distribu...

https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=620917